Bio-Rad Laboratories Statistics
Total Valuation
BIO.B has a market cap or net worth of $8.35 billion. The enterprise value is $8.33 billion.
Important Dates
The last earnings date was Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO.B has 5.07 million shares outstanding. The number of shares has decreased by -3.14% in one year.
| Current Share Class | 5.07M |
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | -3.14% |
| Shares Change (QoQ) | -1.12% |
| Owned by Insiders (%) | 6.53% |
| Owned by Institutions (%) | 72.04% |
| Float | 21.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 29.29 |
| PS Ratio | 3.26 |
| Forward PS | 3.12 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | 24.79 |
| P/OCF Ratio | 16.99 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 19.94, with an EV/FCF ratio of 24.72.
| EV / Earnings | n/a |
| EV / Sales | 3.26 |
| EV / EBITDA | 19.94 |
| EV / EBIT | 32.58 |
| EV / FCF | 24.72 |
Financial Position
The company has a current ratio of 5.44, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.44 |
| Quick Ratio | 3.62 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.88 |
| Debt / FCF | 4.14 |
| Interest Coverage | 5.20 |
Financial Efficiency
Return on equity (ROE) is -9.50% and return on invested capital (ROIC) is 1.88%.
| Return on Equity (ROE) | -9.50% |
| Return on Assets (ROA) | 1.57% |
| Return on Invested Capital (ROIC) | 1.88% |
| Return on Capital Employed (ROCE) | 2.79% |
| Revenue Per Employee | $332,143 |
| Profits Per Employee | -$87,779 |
| Employee Count | 7,700 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | -166.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.66% in the last 52 weeks. The beta is 0.94, so BIO.B's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -8.66% |
| 50-Day Moving Average | 279.73 |
| 200-Day Moving Average | 268.04 |
| Relative Strength Index (RSI) | 62.18 |
| Average Volume (20 Days) | 157 |
Short Selling Information
The latest short interest is 102, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 102 |
| Short Previous Month | 40 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 20.40 |
Income Statement
In the last 12 months, BIO.B had revenue of $2.56 billion and -$675.90 million in losses. Loss per share was -$24.56.
| Revenue | 2.56B |
| Gross Profit | 1.34B |
| Operating Income | 255.50M |
| Pretax Income | -842.60M |
| Net Income | -675.90M |
| EBITDA | 417.60M |
| EBIT | 255.50M |
| Loss Per Share | -$24.56 |
Full Income StatementBalance Sheet
The company has $1.42 billion in cash and $1.40 billion in debt, giving a net cash position of $23.30 million or $4.60 per share.
| Cash & Cash Equivalents | 1.42B |
| Total Debt | 1.40B |
| Net Cash | 23.30M |
| Net Cash Per Share | $4.60 |
| Equity (Book Value) | 6.74B |
| Book Value Per Share | 249.75 |
| Working Capital | 2.32B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $491.50 million and capital expenditures -$154.70 million, giving a free cash flow of $336.80 million.
| Operating Cash Flow | 491.50M |
| Capital Expenditures | -154.70M |
| Free Cash Flow | 336.80M |
| FCF Per Share | $66.45 |
Full Cash Flow StatementMargins
Gross margin is 52.36%, with operating and profit margins of 9.99% and -26.43%.
| Gross Margin | 52.36% |
| Operating Margin | 9.99% |
| Pretax Margin | -32.95% |
| Profit Margin | -26.43% |
| EBITDA Margin | 16.33% |
| EBIT Margin | 9.99% |
| FCF Margin | 13.17% |
Dividends & Yields
BIO.B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.14% |
| Shareholder Yield | 3.14% |
| Earnings Yield | -8.10% |
| FCF Yield | 4.03% |
Analyst Forecast
The average price target for BIO.B is $358.50, which is 17.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $358.50 |
| Price Target Difference | 17.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 1.78% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO.B has an Altman Z-Score of 3.34 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.34 |
| Piotroski F-Score | 4 |
